Patient education and adherence to treatment plans are crucial for effective CSU management.
Non-sedating H1-antihistamines are the first-line treatment, with dosage adjustments based on response.
Omalizumab or cyclosporine may be considered for refractory CSU cases.
Regular follow-ups are essential to monitor treatment efficacy and adjust strategies.
Collaboration with allergists or immunologists can improve outcomes in complex CSU cases.
SHOW MORE
Panelists discuss their advice for dermatologists managing chronic spontaneous urticaria (CSU), emphasizing the importance of individualized treatment plans, and staying updated on emerging therapies and clinical guidelines.